9 completed, 3 terminated. 7 Phase 1, 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Completed 6, Terminated 1 |
| Phase 2 | 7 | Completed 4, Terminated 3 |
Follow cabiralizumab: new trials by email Literature Review of cabiralizumab trials Research Report on cabiralizumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast Cancer Paclitaxel, Carboplatin, Nivolumab - Triple Negative Breast Cancer | Phase 1 / Phase 2 | Terminated | Washington University School of Medicine | 15 | 2020-11-19 | 2026-07-09 |
| Nivolumab + Cabiralizumab + Gemcitabine in Patients With Stage IV Pancreatic Cancer Gemcitabine, Nivolumab 10 MG/ML Intravenous Solution [OPDIVO], Cabiralizumab - Pancreatic Cancer Stage IV | Phase 2 | Completed | Hitendra Patel | 2 | 2019-10-31 | 2025-08-06 |
| Nivolumab Combined With BMS-986253 in HCC Patients Nivolumab 240 mg IV every 2 weeks + Cabiralizumab 4 mg/kg IV every 2 weeks, Nivolumab 240 mg IV every 2 weeks + BMS-986253 1200 mg IV every 2 weeks, Nivolumab 240 mg IV every 2 weeks - Hepatocellular Carcinoma | Phase 2 | Terminated | NYU Langone Health | 13 | 2019-09-12 | 2025-10-16 |
| Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma Nivolumab, cabiralizumab - Peripheral T Cell Lymphoma | Phase 2 | Completed | University of Michigan Rogel Cancer Center | 4 | 2019-04-25 | 2026-05-07 |
| Study of Nivolumab, Cabiralizumab, and Stereotactic Body Radiotherapy (SBRT) for Locally Advanced Unresectable Pancreatic Cancer Nivolumab + Cabiralizumab, Stereotactic Body Radiotherapy (SBRT) - Pancreatic Cancer | Phase 2 | Terminated | NYU Langone Health | 7 | 2018-07-31 | 2021-10-19 |
| APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma APX005M, Cabiralizumab, Nivolumab - Advanced Melanoma, Non-small Cell Lung Cancer | Phase 1 | Completed | Yale University | 42 | 2018-06-09 | 2024-07-03 |
| An Adaptive Study to Match Patients With Solid Tumors to Various Immunotherapy Combinations Based Upon a Broad Biomarker Assessment Nivolumab, Relatlimab, Cabiralizumab - Advanced Cancer | Phase 1 | Completed | Bristol-Myers Squibb | 20 | 2018-05-07 | 2022-09-26 |
| Stereotactic Body Radiotherapy (SBRT) Plus Immunotherapy for Cancer Nivolumab, Cabiralizumab, Urelumab - Cancer | Phase 1 | Completed | University of Chicago | 60 | 2018-03-15 | 2023-02-16 |
| A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer Cabiralizumab, Nab-paclitaxel, Onivyde - Advanced Pancreatic Cancer | Phase 2 | Completed | Bristol-Myers Squibb | 205 | 2017-12-18 | 2024-07-23 |
| A Study of Cabiralzumab Given by Itself or With Nivolumab in Advanced Cancer or Cancer That Has Spread Cabiralizumab, Nivolumab - Advanced Malignancies | Phase 1 | Completed | Bristol-Myers Squibb | 19 | 2017-05-25 | 2020-12-21 |
| Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers Cabiralizumab, Nivolumab - Advanced Solid Tumors, Head and Neck Cancer | Phase 1 | Completed | Five Prime Therapeutics, Inc. | 313 | 2015-09-08 | 2022-03-09 |
| Study of Cabiralizumab in Patients With Pigmented Villonodular Synovitis / Diffuse Type Tenosynovial Giant Cell Tumor FPA008 - Pigmented Villonodular Synovitis, Tenosynovial Giant Cell Tumor | Phase 1 / Phase 2 | Completed | Five Prime Therapeutics, Inc. | 66 | 2015-06-01 | 2021-08-31 |
Pancreatic Neoplasms (3) · Carcinoma, Non-Small-Cell Lung (2) · Carcinoma, Renal Cell (2) · Neoplasms (2) · Carcinoma, Hepatocellular (1) · Giant Cell Tumor of Tendon Sheath (1) · Glioma (1) · Head and Neck Neoplasms (1) · Lymphoma, T-Cell, Peripheral (1) · Ovarian Neoplasms (1) · Synovitis, Pigmented Villonodular (1) · Triple Negative Breast Neoplasms (1)
Bristol-Myers Squibb (3) · Five Prime Therapeutics, Inc. (2) · NYU Langone Health (2) · Hitendra Patel (1) · University of Chicago (1) · University of Michigan Rogel Cancer Center (1) · Washington University School of Medicine (1) · Yale University (1)
United States (11) · Japan (2) · South Korea (2) · United Kingdom (2) · Canada (1) · Denmark (1) · France (1) · Germany (1) · Italy (1) · Netherlands (1) · Poland (1) · Spain (1) · Switzerland (1) · Taiwan (1)
Andrew Davis, M.D. (1) · Andrew Lowy, MD (1) · Deirdre Cohen, MD (1) · Harriet Kluger, MD (1) · Hitendra Patel, MD (1) · Jason Luke, MD (1) · Nina Beri, MD (1) · Ryan Wilcox, MD, PhD (1)
PMID 34140403, PMID 37964379, PMID 40389374
P50CA121974 (1)